Introduction: Angioedema is a potentially fatal adverse drug reaction of some medications, as swellings of the upper airways can cause death by asphyxiation. Angiotensin converting enzymeinhibitors are widely known to cause angioedema but less is known about the association between dipeptidyl peptidase-4 inhibitors (gliptins) and angioedema. Dipeptidyl peptidase-4 inhibitors are antidiabetic drugs used to improve glycaemic control. They, as a class effect, inadvertently affect the degradation of the vasoactive kinins bradykinin and substance P, both of which can cause angioedema due to vasodilatation and increase in vascular permeability in the capillaries.
Objective: To assess the risk and pathomechanism of angioedema due to inhibition of dipeptidyl peptidase- 4 inhibitors when used as monotherapy and in combination with angiotensin converting enzymeinhibitors.
Method: PubMed, Embase, the Cochrane Library, PubMed Central, Web of Science, Google Scholar and clinicaltrials.gov were searched using different combinations of keywords “angioedema”, “dipeptidyl peptidase 4”, “dipeptidyl peptidase 4 inhibitors”, “gliptins”, “bradykinin”, “substance P” and “angiotensin converting enzyme-inhibitors”. Original research papers were preferably used as references and their bibliographies were used to further the search for original research results.
Results: Both angiotensin converting enzyme and dipeptidyl peptidase-4 are major enzymes in the degradation pathway of bradykinin and substance P, and when inhibited pharmacologically – especially at the same time – the theoretical risk of angioedema is increased due to accumulation of vasoactive kinins.
Conclusion: Treatment with dipeptidyl peptidase-4 inhibitors must be carefully considered and monitored especially during concurrent treatment with angiotensin converting enzyme-inhibitors or when treating patients with a known predisposition to angioedema.
Keywords: Angioedema, dipeptidyl peptidase 4 inhibitors, gliptins, bradykinin, substance P, angiotensin converting enzymeinhibitors.
Update on Sensitivity to Nonsteroidal Antiinflammatory Drugs
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Omalizumab: Not Only For Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Substituted Benzimidazole Derivatives as Angiotensin II -AT1 Receptor Antagonist: A Review
Mini-Reviews in Medicinal Chemistry Histamine-Dependent and -Independent Hypersensitivity Reactions to Contrast Media: The Impact of Antihistamines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Hypersensitivity Reactions to Complementary and Alternative Medicine Products
Current Pharmaceutical Design Rapid Desensitization of Hypersensitivity Reactions to Chemotherapy Agents.
Current Drug Safety Adverse Cutaneous Reactions of Systemic Antihistamines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Hypersensitivity Reactions to Non-Steroidal Anti-Inflammatory Drugs
Current Pharmaceutical Design The Safety of Allergen Specific Sublingual Immunotherapy
Current Drug Safety Structure Function Analysis of Serpin Super-Family: "A Computational Approach"
Protein & Peptide Letters Diagnosing β-Lactam Hypersensitivity
Current Pharmaceutical Design Antihistamine Use in Dermatologic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Human Plasma Kallikrein-Kinin System: Physiological and Biochemical Parameters
Cardiovascular & Hematological Agents in Medicinal Chemistry Immediate Hypersensitivity Reactions to Penicillins and Other Betalactams
Current Pharmaceutical Design Inflammation and Coagulation in Urticaria and Angioedema
Current Vascular Pharmacology Hypersensitivity to Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Current Pharmaceutical Design Managing Clopidogrel Hypersensitivity without Interrupting Therapy: The Toronto Approach
Current Vascular Pharmacology Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics
Current Drug Targets Vasopeptidase Inhibition for Blood Pressure Control: Emerging Experience
Current Pharmaceutical Design